Arjo Q3 2026 Adjusted EBITDA Beats at 523M SEK, Margin 18.4%

Arjo, a medical technology firm, reported Q3 2026 adjusted EBITDA of 523 million kronor, with a margin of 18.4%, exceeding expectations. The beat suggests stronger operational performance, likely driven by cost control or revenue mix. This is a single-company earnings surprise, not a macro signal.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works